Full coverage: Multinationals

The Department of Finance described much of the latest bumper corporation tax revenue as a once-off windfall. Yet every indication is that aggressive tax planning through Ireland is set to continue.

When demand for rapid medical tests exploded during the pandemic, the US pharma giant routed this business through Ireland and Malta to achieve a four per cent tax rate. This expanded into a multi-billion-euro business last year.

New information from multiple subsidiaries of the two digital advertising giants in Ireland reveal how they operate in the post-double Irish world and how ready they are to take on the industry slump.

The ride-hailing giant’s Ireland general manager Kieran Harte speaks to The Currency about the country’s taxi shortage and its pitch to government for easing the licensing regime.

Constant hiring by technology firms has just turned into a wave of job cuts. Stephen Kinsella and Thomas Hubert discuss what this means for Ireland – and what the country should do about it.

The US-based visual social and marketing platform hopes to ride out the current tech slump and grow its international business further out of Dublin – despite a major tax setback revealed last year.

The online recruitment firm Indeed recently relocated more of its business to Ireland. So, how big an impact has the reorganisation had on its Irish performance? How much money flows through its Dublin offices? And how much are the 1,242 employees at its main Irish company paid?

The wave of layoffs at technology multinationals is not over. We have been there before and we can learn lessons from the past with policies that limit public finances' reliance on foreign investment and support workers and domestic companies to make the most of the predictable cycle ahead.

The parent of Facebook, Instagram and WhatsApp is the largest yet of technology multinationals to prepare for redundancies in Ireland, illustrating how exposed the Irish economy is to the sector.

The global pharma company targeting rare diseases was acquired for $39 billion by AstraZeneca last year. Half of this value consisted in intellectual property located in Dublin, new documents show.